Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure · Investor's Business Daily

In This Article:

Summit Therapeutics stock plunged Friday after its highly watched cancer drug failed to significantly improve overall survival.